Skip to content Skip to footer
Subscribe Now
MAGAZINE

PharmaShots Magazine-May-2026 Edition

Shots: PharmaShots’ May Edition explores how AI is transforming commercial strategies across the healthcare ecosystem by enabling predictive analytics, personalized engagement, dynamic launch planning, and real-time omnichannel optimization while balancing compliance and measurable ROI. The magazine highlights key industry movements shaping global biopharma, including AI-driven drug discovery collaborations, strategic M&A activity, advancements in cell and…
May 14, 2026

Read more

EVENTS

2026 HLTH Europe | June 15-18 | Amsterdam

HLTH Europe is the continent’s #1 healthcare innovation event. Following an enormously successful launch and the exponential growth of HLTH in the US, this landmark event is where global expertise meets local insight to address Europe’s unique healthcare challenges and opportunities. Unlock an exclusive €250 discount with PharmaShots! Use code HE26PHARMASHOTS at checkout to save…
May 14, 2026

Read more

INSIGHTS+

The US FDA New Drug Approvals in April 2026 

Shots:  Approval activity continued strongly into April 2026, with the US FDA authorizing two significant therapies across metabolic disease and infectious disease, reinforcing the agency’s focus on chronic disease management, long-term treatment innovation, and broader patient access.  Two notable therapies achieved regulatory clearance: Eli Lilly’s Foundayo for weight loss in obese or overweight adults with weight-related conditions,…
May 12, 2026

Read more

THOUGHTSPOT

CEAS Collective: Bridging Biotech Innovation and Consumer Wellness Through Direct-to-Patient Delivery 

Biotech innovation is rapidly transforming the boundaries of modern wellness, and CEAS  Collective stands at the forefront of this shift. By integrating advanced product  development with a direct-to-patient delivery model, CEAS Collective bridges the gap  between next-generation health solutions and consumer-centric care. Their approach  sets a new benchmark for accessible, holistic wellness, offering patients seamless  access to science-driven products…
May 11, 2026

Read more

VIEWPOINTS

Ending Prescription Ping-Pong in Specialty Care: Colin Banas, CMO, Timely By DrFirst Shares His Vision  

Shots:  Specialty medication access remains challenged by high costs, fragmented workflows, complex prior authorization requirements, and limited transparency, leading to delays, prescription drop-offs, and suboptimal patient outcomes.  DrFirst is addressing these gaps through AI-powered, workflow-integrated solutions that enable real-time benefits verification, targeted prior authorization automation, and smarter pharmacy routing, shifting care from reactive problem-solving to proactive, frictionless prescribing.  PharmaShots welcomes…
May 4, 2026

Read more

INSIGHTS+

The US FDA New Drug Approvals in March 2026 

Shots:  Approval momentum accelerated in late March 2026, with the US FDA clearing five new therapies across hepatology, dermatology, rare genetic disorders, oncology, and endocrinology; highlighting both therapeutic breadth and meaningful clinical impact.  Five notable therapies crossed the regulatory finish line: GSK’s Lynavoy for cholestatic pruritus in primary biliary cholangitis, Johnson & Johnson’s Icotyde for moderate-to-severe plaque psoriasis, Denali…
April 14, 2026

Read more

VIEWPOINTS

Innovation Meets Impact: Jaime Leija on BioLab’s Patient-First Approach

Shots:  BioLab balances innovation with real-world impact through a dual strategy that combines rapid commercialization of FDA-approved or near-market solutions like Imbed with continued investment in long-term innovations such as cureVision and terraplasma, ensuring both immediate clinical needs and future breakthroughs in wound care are effectively addressed.    BioLab’s growth is driven by sharp strategic discipline, focusing on chronic outpatient…
April 13, 2026

Read more

INSIGHTS+

Key Biosimilars Events of March 2026 

Shots:  Regulatory momentum remained strong, with key biosimilar launches and approvals including Celltrion’s Remsima IV (EU) and Avtozma SC (US), Teva’s FDA-approved Ponlimsi, Japan’s approval of tocilizumab BS MA by Mochida Pharmaceutical and AYUMI Pharmaceutical, and IND clearance for HLX18 by National Medical Products Administration.  Strategic partnerships expanded access, led by Samsung Bioepis–Sandoz collaboration, Formycon’s aflibercept settlement deal with Regeneron Pharmaceuticals and Bayer, and Bio-Thera…
April 7, 2026

Read more

EVENTS

Future Biotech Expo 2026 | June 02-03 | Hilton Houston North, TX, USA

The Future Biotech Expo is a premier international red biotechnology exhibition and conference dedicated to accelerating breakthroughs across the industry vertical that are shaping the future of healthcare and medicine across the globe and beyond.  Future Biotech Expo features a world-class exhibition, thought-provoking conferences, startup showcases, structured B2B matchmaking, and a dedicated Hosted Buyer Program…
April 2, 2026

Read more

INSIGHTS+

EMA Marketing Authorization of New Drugs in February 2026    

Shots:  The European Commission approved multiple innovative therapies across vaccines, oncology, cardiology, immunology, and rare diseases, including products from Moderna, Hansoh Pharmaceutical, Cytokinetics, ImmunityBio, and GSK  The Committee for Medicinal Products for Human Use also issued positive opinions for late-stage assets from Ipsen, X4 Pharmaceuticals, Novartis, and Moderna, alongside additional recommendations for therapies targeting chronic spontaneous urticaria, WHIM syndrome, pediatric…
March 17, 2026

Read more

Load more